US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Range Cancer Therapeutics ETF

9.02

0.0000

Volume:- -

Turnover:- -

Market Cap:7.04M

PE:23.74

High:9.02

Open:9.02

Low:9.02

Close:9.02

52wk High:9.02

52wk Low:9.02

Shares:780.81K

Float Shares:780.81K

Volume Ratio:- -

T/O Rate:- -

Dividend:0.00

Dividend Rate:0.01%

EPS(TTM):0.3800

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ultragenyx announces FDA accelerated approval of Genglycos

Genprex selects manufacturing organization for diabetes gene therapy

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029

Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference

FDA Awards Fast Track Status to Xellsmart's Ready-to-Use Cell Therapy for Parkinson's Disease

Lantern Pharma Spins Off Open-Medicine AI Platform

ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)

Pacira transitions PCRX-201 to a U.S.-based manufacturing process

Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma

Tripartite Agreement Establishes First Greater Bay Area International Clinical Hub, Focusing on AI Scoliosis Screening and Stem Cell Therapy for Osteoarthritis

Ernexa Therapeutics announces new ERNA-101 preclinical data

Voyager Therapeutics advances tau-silencing gene therapy program

StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CNCR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CNCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1787342400000,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","floatShares":780814,"roa":"--","roe":"--","lyrEps":0,"shares":780814,"dividePrice":0.001,"high":9.02,"amplitude":0,"preClose":9.02,"low":9.02,"week52Low":9.02,"pbRate":"--","week52High":9.02,"institutionHeld":0,"latestPrice":9.02,"eps":0.38,"divideRate":0.000111,"volume":0,"delay":0,"ttmEps":0.38,"open":9.02,"prevYearClose":9.02,"prevWeekClose":9.02,"prevMonthClose":9.02,"prevQuarterClose":9.02,"fiveDayClose":9.02,"twentyDayClose":9.02,"sixtyDayClose":9.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-28","symbol":"CNCR","reason":null,"defaultRemindTime":1748439000000,"announcedDate":"2025-05-27","type":"delisting","dateTimestamp":1748404800000},{"market":"US","date":"2021-12-29","symbol":"CNCR","amount":1.8533352,"defaultRemindTime":1640788200000,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000},{"market":"US","date":"2020-12-30","symbol":"CNCR","amount":0.2881193,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-01-04","payableDate":"2020-12-31","currency":"USD","type":"dividend","dateTimestamp":1609304400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNCR\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-30","recordDate":"2020-12-31","paymentDate":"2021-01-04","value":0.2881193,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":1.8533352,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNCR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNCR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660885476","title":"Ultragenyx announces FDA accelerated approval of Genglycos","url":"https://stock-news.laohu8.com/highlight/detail?id=2660885476","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660885476?lang=en_us&edition=fundamental","pubTime":"2026-08-20 05:25","pubTimestamp":1787174717,"startTime":"0","endTime":"0","summary":"Ultragenyx (RARE) Pharmaceutical announced that the FDA granted accelerated approval for Genglycos, also known as DTX401, in adult and pediatric pa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ultragenyx-announces-fda-accelerated-approval-of-genglycos-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ultragenyx-announces-fda-accelerated-approval-of-genglycos-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CNCR","LABU","BK4139","RARE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461015","title":"Genprex selects manufacturing organization for diabetes gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461015","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461015?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051418,"startTime":"0","endTime":"0","summary":"Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","FBT","LFSC","GNPX","SYNB","BK4585","TBXU","BK4139","BK4588","EES","IBBQ","IBB","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","GDOC","SYNB","BK4585","IBBQ","BK4588","HYLG","BK4022","FBT","CAR","BK4539","LD","NVIB","CNCR","PFS","LFSC","CRBU","BK4139","BK4161","IBB","IDNA","BK4211","BK4230","GNOM","TBXU","MEDX","ORR","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658657916","title":"Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658657916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658657916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:01","pubTimestamp":1786456868,"startTime":"0","endTime":"0","summary":"Neurogene ( ($NGNE) ) just unveiled an announcement. Neurogene reported strong progress in its NGN-401 gene therapy program for Rett syndrome, high...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GNOM","CNCR","SYNB","IBBQ","LFSC","IBB","TBXU","BK4585","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657369495","title":"Oxford Biomedica trims 2026 outlook but leans on record client wins and growing pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657369495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657369495?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:11","pubTimestamp":1786083103,"startTime":"0","endTime":"0","summary":"An update from Oxford BioMedica ( ($GB:OXB) ) is now available. Oxford Biomedica, a specialist cell and gene therapy CDMO, reported around 9% reven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oxford-biomedica-trims-2026-outlook-but-leans-on-record-client-wins-and-growing-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","JDOC","WDNA","TBXU","IBBQ","IDNA","SYNB","BK4585","BK4588","IBB","LFSC","CNCR","GNOM","OXM","HELX","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669317","title":"Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669317","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669317?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:50","pubTimestamp":1786053037,"startTime":"0","endTime":"0","summary":"Replimune (REPL) announced that the FDA has granted accelerated approval for Tudriqev, previously referred to as RP1, in combination with nivolumab...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-announces-fda-accelerated-approval-of-tudriqev-for-advanced-melanoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-announces-fda-accelerated-approval-of-tudriqev-for-advanced-melanoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4588","LABU","BK4139","CNCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657023575","title":"Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657023575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657023575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:45","pubTimestamp":1785995139,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has shared an announcement. Circio Holding ASA, a biotechnology company specializing in circular RNA expression systems...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circios-circvec-gene-therapy-platform-secures-oral-slot-at-top-european-esgct-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","JDOC","TBXU","SYNB","EPV","LNGR","IEIH","LFSC","BK4585","BK4139","BK4505","RNA","FHLC","AGNG","IBB","BK4588","FWD","GNOM","CNCR","IE0009354923.USD","XT","RDMX","RSPH","BBP","DARP","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102454005","title":"FDA Awards Fast Track Status to Xellsmart's Ready-to-Use Cell Therapy for Parkinson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1102454005","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102454005?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:24","pubTimestamp":1785849887,"startTime":"0","endTime":"0","summary":"FDA Grants Fast Track Status for Xellsmart's Parkinson's Cell TherapyXellSmart's proprietary off-the-shelf iPSC-derived cell therapy, XS411, has received Fast Track designation from the U.S. Food and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNCR","BK4585","WDNA","SYNB","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300531","title":"Lantern Pharma Spins Off Open-Medicine AI Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300531?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:18","pubTimestamp":1785795515,"startTime":"0","endTime":"0","summary":"Lantern Pharma ( ($LTRN) ) has issued an update. Lantern Pharma Inc., listed on Nasdaq as LTRN, is a clinical-stage precision oncology company that...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lantern-pharma-spins-off-open-medicine-ai-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lantern-pharma-spins-off-open-medicine-ai-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","QTOC","BK4139","ARTY","LTRN","AIPO","CNCR","VTHR","NQmain","CHAT","LCLG","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302838","title":"ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302838","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302838?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789624,"startTime":"0","endTime":"0","summary":"Reports Q2 revenue $10.88M, consensus $12.73M. “Establishing ClearPoint Neuro (CLPT) as the leading neuro cell and gene therapy delivery company ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearpoint-neuro-reports-q2-eps-38c-consensus-29c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","BK4082","CLPT","BK4588","IDNA","FBT","IBBQ","WDNA","GNOM","SYNB","CNCR","HELX","TBXU","LFSC","IBB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010362","title":"Pacira transitions PCRX-201 to a U.S.-based manufacturing process","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010362?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:10","pubTimestamp":1785154247,"startTime":"0","endTime":"0","summary":"Pacira (PCRX) announced that it has successfully transitioned PCRX-201, its investigational locally administered gene therapy for osteoarthritis of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pacira-transitions-pcrx-201-to-a-u-s-based-manufacturing-process-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pacira-transitions-pcrx-201-to-a-u-s-based-manufacturing-process-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EES","FBT","IBBQ","PCRX","GNOM","SYNB","CNCR","BK4007","TBXU","LFSC","IBB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652425738","title":"Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2652425738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652425738?lang=en_us&edition=fundamental","pubTime":"2026-07-17 00:31","pubTimestamp":1784219512,"startTime":"0","endTime":"0","summary":"Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The long term follow up study of AAVAnc80-antiVEGF gene therapy a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lilly-backed-gene-therapy-study-tracks-long-term-safety-in-vestibular-schwannoma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lilly-backed-gene-therapy-study-tracks-long-term-safety-in-vestibular-schwannoma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","FBT","LFSC","SYNB","BK4585","BK4588","IBBQ","IBB","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151639443","title":"Tripartite Agreement Establishes First Greater Bay Area International Clinical Hub, Focusing on AI Scoliosis Screening and Stem Cell Therapy for Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=1151639443","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151639443?lang=en_us&edition=fundamental","pubTime":"2026-07-16 13:31","pubTimestamp":1784179908,"startTime":"0","endTime":"0","summary":"A tripartite cooperation agreement was signed today, July 15th, between The Chinese University of Hong Kong (CUHK), the People's Government of Nansha District, Guangzhou, and Guangzhou First People's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNCR","CHAT","AGIX","AIPO","ARTY","SYNB","WDNA","QTOC","VTHR","159983"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646874","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646874?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:15","pubTimestamp":1784117721,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","LFSC","GNOM","IBBQ","CNCR","FBT","ERNA","SYNB","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145087","title":"Voyager Therapeutics advances tau-silencing gene therapy program","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145087","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145087?lang=en_us&edition=fundamental","pubTime":"2026-07-14 01:27","pubTimestamp":1783963636,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory prac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-advances-tau-silencing-gene-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","IBBQ","CNCR","SYNB","BK4588","LFSC","BK4585","IBB","VYGR","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649963787","title":"StemRIM Wins South Korean Patent for Gene Therapy Targeting Rare Skin Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2649963787","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649963787?lang=en_us&edition=fundamental","pubTime":"2026-07-08 14:54","pubTimestamp":1783493684,"startTime":"0","endTime":"0","summary":"StemRIM Inc. ( ($JP:4599) ) has shared an update. StemRIM Inc. has secured patent protection in South Korea for a stem cell gene therapy technology...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-south-korean-patent-for-gene-therapy-targeting-rare-skin-disorder?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stemrim-wins-south-korean-patent-for-gene-therapy-targeting-rare-skin-disorder?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","CNCR","BK4585","GNOM","IBB","IBBQ","SYNB","USRD","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}